FDA approves new pancreatic cancer drug that could extend patients' lives

Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.

  Health   Sep 3, 2026   0   9  Add to Reading List
FDA approves new pancreatic cancer drug that could extend patients' lives












Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow